Clinical trial NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Official title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Plaque Psoriasis
Keywords: Latitude Psoriasis 3
Latitude Research Program
Latitude PsO OLE
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2024-08-12
Enrollment: 1300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Detailed description: This study consists of 2 parts: Part A and Part B.

Part A: Participants who did not participate in either parent study (TAK-279-3001 \[NCT06088043\] or TAK-279-3002 \[NCT06108544\]) may be enrolled and will be treated for up to 52 weeks. Participants who successfully complete Part A of the study are eligible to continue in Part B, but investigators must confirm their eligibility to continue in Part B.

Part B: Participants who complete the treatment period of TAK-279-3001 (NCT06088043) or TAK-279-3002 (NCT06108544) parent studies or who complete Part A are eligible to enroll directly into open label extension treatment in Part B and will be treated for up to 156 weeks.

Eligibility criteria: Main Inclusion Criteria:

Part A:

* Participant is willing and able to understand and fully comply with study procedures and requirements (including digital tools and applications), in the opinion of the investigator.
* Participant has provided written informed consent and any required privacy authorization before the initiation of any study procedures.
* Participant is aged 18 years or older at the time of consent.
* Participant has a diagnosis of chronic plaque psoriasis for \>=6 months prior to the screening visit.
* Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for \>=6 months before screening.
* Participant has moderate-to-severe plaque psoriasis as defined by a PASI score \>=12 and a sPGA score \>=3 at screening and Day 1.
* Participant has plaque psoriasis covering \>=10% of his or her total BSA at screening and Day 1.
* Participant must be a candidate for phototherapy or systemic therapy.

Part B:

- Participant has completed 52 weeks of treatment (TAK-279-3001 or Part A) or 60 weeks of treatment (TAK-279-3002) in their parent study or Part A.

Main Exclusion Criteria

Part A:

* Participant has evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary.
* Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune-related disease (e.g., inflammatory bowel disease).
* Participant has any clinically significant medical condition, evidence of an unstable clinical condition (e.g., cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. These include but are not limited to:

  1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy.
  2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the study.
  3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.
  4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria.
  5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
  6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.
  7. Participant has any of the following cardiovascular disease history: A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, non-acute cardiac hospitalization (e.g., pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll.
  8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the study, in the opinion of the investigator.
  9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator.
  10. Participant has any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by 1) medical history; or 2) by Columbia-Suicide Severity Rating Scale (C-SSRS) documentation at screening or by answering "yes" to Question 5 for suicidal ideation on the C-SSRS at screening; or 3) is clinically deemed to have a suicide risk by the investigator.
  11. Participant has a patient health questionnaire - 8 (PHQ-8) score of 15 or above at screening.
  12. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1.
* Participant has received any of the following biologics or biosimilar versions within the time frame indicated or 5 half-lives, whichever is longer:

  1. Antibodies to interleukin (IL) -12/-23, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1.
  2. Tumor necrosis factor inhibitor(s) (e.g., etanercept, adalimumab, infliximab, certolizumab) within 2 months prior to Day 1.
  3. Agents that modulate integrin pathways to impact lymphocyte trafficking (e.g., natalizumab) or agents that modulate B cells or T cells (e.g., alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1.
  4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1.
* Participant has any previous exposure to TAK-279 (also known as NDI-034858) or other TYK2 inhibitors, including deucravacitinib, or participant participated in any study that included a TYK2 inhibitor (e.g., deucravacitinib, VTX958, GLPG3667, etc.), unless the participant has documentation of post-trial unblinding that confirms the partcipant did not receive a TYK2 inhibitor.
* Participant has a known or suspected allergy to TAK-279 or any of its components.

Part B:

* Participant has completed the parent study or Part A but was permanently discontinued from treatment.
* Participant had evidence of significant noncompliance with study visits or study drug in the parent study or Part A, as defined in the parent study protocol or in the opinion of the investigator.
* Participant has met criteria for termination from the parent study or Part A, regardless of whether or not the participant was terminated from the parent study or Part A.
* Participant has developed evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis) since enrollment in the parent study or Part A.
* Participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments.
* Participant has received a prohibited psoriasis treatment during the parent study or Part A, whether or not that treatment was documented as a concomitant medication and is expected to continue that treatment.

Primary outcomes:
measure: Part A and Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
timeFrame: From start of the drug administration up to Week 56 (Part A) and Week 160 (Part B)
Secondary outcomes:
measure: Part A and B: Number of Participants Achieving 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI-75) Score
timeFrame: Baseline up to Week 52 (Part A) and Week 156 (Part B)
measure: Part A and B: Number of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a >=2-point Decrease from Baseline
timeFrame: Baseline up to Week 52 (Part A) and Week 156 (Part B)
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Total Dermatology
state: Alabama
city: Birmingham
country: United States
facility: University of Alabama Hospital - Whitaker Clinic -
state: Alabama
city: Hoover
country: United States
facility: Cahaba Dermatology Skin Health Center
state: Alabama
city: Phoenix
country: United States
facility: Medical Dermatology Specialists
state: Arizona
city: Phoenix
country: United States
facility: Saguaro Dermatology Associates, LLC - Probity - PPDS
state: Arizona
city: Tucson
country: United States
facility: Noble Clinical Research
state: Arizona
city: Fort Smith
country: United States
facility: Johnson Dermatology Clinic
state: Arkansas
city: Hot Springs
country: United States
facility: Burke Pharmaceutical Research
state: Arkansas
city: Beverly Hills
country: United States
facility: Zenith Research, Inc.
state: California
city: Fountain Valley
country: United States
facility: First OC Dermatology Research Inc.
state: California
city: Fremont
country: United States
facility: Center for Dermatology Clinical Research
state: California
city: Long Beach
country: United States
facility: Long Beach Research Institute
state: California
city: Los Angeles
country: United States
facility: Metropolis Dermatology Downtown LA - Probity - PPDS
state: California
city: Los Angeles
country: United States
facility: UCLA University of California Los Angeles
state: California
city: Northridge
country: United States
facility: Northridge Clinical Trials
state: California
city: Sacramento
country: United States
facility: UC Davis Dermatology Clinic
state: California
city: San Diego
country: United States
facility: TCR Medical Corporation
state: California
city: San Diego
country: United States
facility: University Clinical Trials
state: California
city: Santa Monica
country: United States
facility: Dermatology Institute and Skin Care Center
state: California
city: Sherman Oaks
country: United States
facility: UNISON Clinical Trials (Shahram Jacobs md inc.)
state: California
city: Coral Gables
country: United States
facility: Driven Research LLC
state: Florida
city: Doral
country: United States
facility: Revival Research Corporation - Florida - ClinEdge - PPDS
state: Florida
city: Fort Lauderdale
country: United States
facility: FXM Clinical Research Ft. Lauderdale, LLC
state: Florida
city: Hialeah
country: United States
facility: Direct Helpers Medical Center
state: Florida
city: Miami Lakes
country: United States
facility: San Marcus Research Clinic Inc
state: Florida
city: Miami
country: United States
facility: Florida Academic Centers Research
state: Florida
city: Miami
country: United States
facility: FXM Clinical Research Miami, LLC
state: Florida
city: Miramar
country: United States
facility: FXM Research Miramar
state: Florida
city: Ocala
country: United States
facility: Renstar Medical Research -21 NE 1st Ave
state: Florida
city: Sweetwater
country: United States
facility: Lenus Research & Medical Group
state: Florida
city: Tampa
country: United States
facility: Advanced Clinical Research Institute (ACRI) - Florida
state: Florida
city: Atlanta
country: United States
facility: Divine Dermatology and Aesthetics, LLC
state: Georgia
city: Marietta
country: United States
facility: Marietta Dermatology & The Skin Cancer Center - Marietta
state: Georgia
city: Sandy Springs
country: United States
facility: Advanced Medical Research, PC
state: Georgia
city: Savannah
country: United States
facility: Georgia Skin and Cancer Clinic
state: Georgia
city: Idaho Falls
country: United States
facility: Leavitt Clinical Research
state: Idaho
city: Rolling Meadows
country: United States
facility: Arlington Dermatology
state: Illinois
city: Skokie
country: United States
facility: NorthShore Medical Group Dermatology - Skokie
state: Illinois
city: Clarksville
country: United States
facility: DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location
state: Indiana
city: Indianapolis
country: United States
facility: Dawes Fretzin Clinical Research Group, LLC
state: Indiana
city: Louisville
country: United States
facility: Skin Sciences, PLLC
state: Kentucky
city: Louisville
country: United States
facility: Dermatology Specialists Research - 3810 Springhurst Blvd
state: Kentucky
city: Rockville
country: United States
facility: Lawrence J Green, MD LLC
state: Maryland
city: Ann Arbor
country: United States
facility: University of Michigan Hospital - 1500 E Medical Center Dr
state: Michigan
city: Auburn Hills
country: United States
facility: Oakland Hills Dermatology - 3400 Auburn Rd
state: Michigan
city: Troy
country: United States
facility: Revival Research Corporation - ClinEdge
state: Michigan
city: New Brighton
country: United States
facility: Minnesota Clinical Study Center
state: Minnesota
city: Omaha
country: United States
facility: Skin Specialists PC
state: Nebraska
city: Henderson
country: United States
facility: Henderson Clinical Trials
state: Nevada
city: Lebanon
country: United States
facility: Dartmouth Hitchcock Medical Center - Old Etna Rd
state: New Hampshire
city: Portsmouth
country: United States
facility: ALLCUTIS Research, LLC.
state: New Hampshire
city: East Windsor
country: United States
facility: Psoriasis Treatment Center of Central New Jersey
state: New Jersey
city: Bronx
country: United States
facility: Montefiore AOA - BRANY
state: New York
city: New York
country: United States
facility: Sadick Research Group
state: New York
city: Cary
country: United States
facility: Accellacare of Cary
state: North Carolina
city: Winston-Salem
country: United States
facility: The Skin Surgery Center for Clinical Research - Objective Health - PPDS
state: North Carolina
city: Bexley
country: United States
facility: Bexley Dermatology Research - Probity - PPDS
state: Ohio
city: Fairborn
country: United States
facility: Wright State Physicians
state: Ohio
city: Mayfield Heights
country: United States
facility: Apex Clinical Research Center
state: Ohio
city: Portland
country: United States
facility: Oregon Medical Research Center PC
state: Oregon
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center-3601 5th Ave
state: Pennsylvania
city: Hermitage
country: United States
facility: Cumberland Skin Center for Clinical Research - Objective Health - PPDS
state: Tennessee
city: Murfreesboro
country: United States
facility: International Clinical Research US LLC
state: Tennessee
city: Arlington
country: United States
facility: Arlington Research Center
state: Texas
city: Bellaire
country: United States
facility: Bellaire Dermatology Associates
state: Texas
city: Bellaire
country: United States
facility: UT Physicians Dermatology - Bellaire Station
state: Texas
city: Dallas
country: United States
facility: Modern Research Associates
state: Texas
city: Frisco
country: United States
facility: North Texas Center for Clinical Research
state: Texas
city: San Antonio
country: United States
facility: San Antonio
state: Texas
city: San Antonio
country: United States
facility: Texas Dermatology and Laser Specialists-San Antonio-7703 Floyd Curl Dr
state: Texas
city: San Antonio
country: United States
facility: Dermatology Clinical Research Center of San Antonio
state: Texas
city: Sugar Land
country: United States
facility: Houston Center for Clinical Research, LLC
state: Texas
city: Webster
country: United States
facility: Center For Clinical Studies, LTD. LLP - 451 N Texas Ave
state: Texas
city: Norfolk
country: United States
facility: Virginia Clinical Research - 6160 Kempsville Cir
state: Virginia
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Conexa Investigación Clínica S.A.
state: Ciudad Autónoma De BuenosAires
city: San Miguel de Tucuman
country: Argentina
facility: Centro de Investigaciones Médicas Tucumán
state: Tucumán
city: Buenos Aires
country: Argentina
facility: Instituto de Dermatología y Neumonología
city: Ciudad Autónomade Buenos Aires
country: Argentina
facility: Centro de Investigacion Clinica
city: Kogarah
country: Australia
facility: St George Dermatology and Skin Cancer Center - Probity - PPDS
state: New South Wales
city: Benowa
country: Australia
facility: The Skin Center - Probity
state: Queensland
city: Carlton
country: Australia
facility: Skin Health Institute Inc - Probity - PPDS
state: Victoria
city: Parkville
country: Australia
facility: Alfred Health
state: Victoria
city: Parkville
country: Australia
facility: Western Health - Sunshine Hospital
state: Victoria
city: Sevlievo
country: Bulgaria
facility: Medical Center Unimed EOOD-Sevlievo
state: Gabrovo
city: Dupnitsa
country: Bulgaria
facility: Medical Center Asklepii OOD
state: Kjustendil
city: Sofia
country: Bulgaria
facility: Diagnostic and Consulting Center Aleksandrovska EOOD
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: Diagnostic Consultative Centre - Focus-5 - LZIP EOOD
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: Medical Center Hera EOOD-Sofia
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: Diagnostic Consultative Center XXVIII - Sofia - EOOD
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: MC Comac Medical
state: Sofia-Grad
city: Gabrovo
country: Bulgaria
facility: Multiprofile Hospital For Active Treatment Dr Tota Venkova
city: Haskovo
country: Bulgaria
facility: Diagnostic Consultative Center Sveti
city: Pleven
country: Bulgaria
facility: Medical Center Medconsult Pleven OOD
city: Calgary
country: Canada
facility: Beacon Dermatology - Probity
state: Alberta
city: Calgary
country: Canada
facility: Dermatology Research Institute, Inc.
state: Alberta
city: Edmonton
country: Canada
facility: Alberta DermaSurgery Centre - Probity
state: Alberta
city: Edmonton
country: Canada
facility: VIDA Dermatology - Probity
state: Alberta
city: Red Deer
country: Canada
facility: Care Clinic
state: Alberta
city: Surrey
country: Canada
facility: Enverus Medical Research - Probity
state: British Columbia
city: Winnipeg
country: Canada
facility: Wiseman Dermatology Research Inc.
state: Manitoba
city: St. John's
country: Canada
facility: Karma Clinical Trials
state: Newfoundland and Labrador
city: Ajax
country: Canada
facility: CCA Medical Research - Probity
state: Ontario
city: Barrie
country: Canada
facility: SimcoDerm Medical and Surgical Dermatology Centre - Probity
state: Ontario
city: Etobicoke
country: Canada
facility: Kingsway Clinical Research - Probity
state: Ontario
city: Guelph
country: Canada
facility: Guelph Dermatology Research - Probity
state: Ontario
city: Hamilton
country: Canada
facility: Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity
state: Ontario
city: Hamilton
country: Canada
facility: Dermatrials Research
state: Ontario
city: London
country: Canada
facility: Mediprobe Research Inc
state: Ontario
city: London
country: Canada
facility: DermEffects
state: Ontario
city: Markham
country: Canada
facility: Lynderm Research Inc - Probity
state: Ontario
city: Mississauga
country: Canada
facility: DermEdge Research - Probity
state: Ontario
city: Newmarket
country: Canada
facility: Dr. S. K. Siddha Medicine Professional Corporation | Newmarket, Canada
state: Ontario
city: North Bay
country: Canada
facility: North Bay Dermatology Center - Probity
state: Ontario
city: Oakville
country: Canada
facility: The Centre for Clinical Trials Inc.
state: Ontario
city: Peterborough
country: Canada
facility: Skin Centre for Dermatology
state: Ontario
city: Richmond Hill
country: Canada
facility: The Centre For Dermatology
state: Ontario
city: Toronto
country: Canada
facility: North York Research Inc. - Probity
state: Ontario
city: Toronto
country: Canada
facility: Canadian Dermatology Centre - Probity
state: Ontario
city: Toronto
country: Canada
facility: Toronto Research Centre
state: Ontario
city: Toronto
country: Canada
facility: Toronto Research Centre - Probity
state: Ontario
city: Waterloo
country: Canada
facility: Alliance Clinical Trials
state: Ontario
city: Windsor
country: Canada
facility: XLR8 Medical Research
state: Ontario
city: Montreal
country: Canada
facility: Siena Medical Research Corporation
state: Quebec
city: Saskatoon
country: Canada
facility: Skinsense Medical Research - Probity
state: Saskatchewan
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University
state: Beijing
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Tongren Hospital, Capital Medical University
state: Beijing
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
city: Fuzhou
country: China
facility: The First Affiliated Hospital of Fujian Medical University
state: Fujian
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Dermatology Hospital of Southern Medical University
state: Guangdong
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
state: Guangdong
city: Guangzhou
country: China
facility: Zhujiang Hospital of Southern Medical University
state: Guangdong
city: Shijiazhuang
country: China
facility: The First Hospital of Hebei Medical University
state: Hebei
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)
state: Hubei
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
state: Hubei
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
city: Zhenjiang
country: China
facility: Affiliated Hospital of Jiangsu University
state: Jiangsu
city: Shanghai
country: China
facility: Huashan Hospital Fudan University - PPDS
state: Minhang District
city: Yinchuan
country: China
facility: General Hospital of Ningxia Medical University
state: Ningxia
city: Jinan
country: China
facility: Shandong Provincial Hospital
state: Shandong
city: Shanghai
country: China
facility: Shanghai Skin Disease Hospital
state: Shanghai
city: Taiyuan
country: China
facility: First Hospital of Shanxi Medical University
state: Shanxi
city: Xi'an
country: China
facility: The 2nd Hospital of Xi'An Jiaotong University
state: Shanxi
city: Chengdu
country: China
facility: West China Hospital Sichuan University
state: Sichuan
city: Hangzhou
country: China
facility: Zhejiang Provincial People's Hospital
state: Zhejiang
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital Zhejiang University School of Medicine
state: Zhejiang
city: Wenzhou
country: China
facility: The 1st Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
city: Shenzhen
country: China
facility: The University of Hong Kong - Shenzhen Hospital
city: Brno
country: Czechia
facility: Pratia Brno s.r.o. - PRATIA - PPDS
state: Jihomoravský Kraj
city: Nachod
country: Czechia
facility: Dermamedica, s.r.o. - Kozni Ambulance Nachod
state: Královéhradecký Kraj
city: Nový Jičín
country: Czechia
facility: Nemocnice AGEL Novy Jicin a.s
state: Moravskoslezský Kraj
city: Ostrava
country: Czechia
facility: CCR Ostrava s.r.o.
state: Moravskoslezský Kraj
city: Olomouc
country: Czechia
facility: Dermskin s.r.o
state: Olomoucký Kraj
city: Pardubice
country: Czechia
facility: Pratia Pardubice a.s. - PRATIA - PPDS
state: Pardubický Kraj
city: Prague
country: Czechia
facility: Praglandia
city: Praha 10
country: Czechia
facility: CLINTRIAL s.r.o.
city: Praha 10
country: Czechia
facility: Fakultni nemocnice Kralovske Vinohrady
city: Praha 1
country: Czechia
facility: Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS
city: Blankenfelde-Mahlow
country: Germany
facility: Hautarztpraxis Mahlow
state: Brandenburg
city: Bad Bentheim
country: Germany
facility: Fachklinik Bad Bentheim
state: Niedersachsen
city: Oldenburg
country: Germany
facility: Klinikum Oldenburg
state: Niedersachsen
city: Dresden
country: Germany
facility: Klinische Forschung Dresden Gmbh
state: Sachsen
city: Dresden
country: Germany
facility: Praxis fur Dermatologie and Venerologie
state: Sachsen
city: Gera
country: Germany
facility: SRH Wald-Klinikum Gera GmbH
state: Thüringen
city: Hamburg
country: Germany
facility: Dermatologikum Hamburg
city: Szolnok
country: Hungary
facility: Allergo-Derm Bakos Kft.
state: Jász-Nagykun-Szolnok
city: Kaposvár
country: Hungary
facility: Somogy Megyei Kaposi Mór Oktató Kórház
state: Somogy
city: Szombathely
country: Hungary
facility: Markusovszky Egyetemi Oktatókórház
state: Vas
city: Debrecen
country: Hungary
facility: Debreceni Egyetem
city: Petach Tikva
country: Israel
facility: Rabin Medical Center - PPDS
city: Ramat Gan
country: Israel
facility: Chaim Sheba Medical Center
city: Rozzano
country: Italy
facility: IRCCS Istituto Clinico Humanitas
state: Milano
city: Catania
country: Italy
facility: Presidio Ospedaliero Gaspare Rodolico
state: Sicilia
city: Firenze
country: Italy
facility: Azienda Usl Toscana Centro - Firenze
state: Toscana
city: Nagoya-City
country: Japan
facility: Nagoya City University Hospital
state: Aichi
city: Obihiro-Shi
country: Japan
facility: Takagi Dermatological Clinic
state: Hokkaidô
city: Sapporo-Shi
country: Japan
facility: JR Sapporo Hospital
state: Hokkaidô
city: Sapporo-Shi
country: Japan
facility: Medical Corporation Kojinkai Sapporo Skin Clinic
state: Hokkaidô
city: Fukuoka-Shi
country: Japan
facility: Fukuoka University Hospital
state: Hukuoka
city: Shimotsuke-shi
country: Japan
facility: Jichi Medical University Hospital
state: Tochigi-Ken
city: Shinjuku-ku
country: Japan
facility: JCHO Tokyo Yamate Medical Center
state: Tokyo-To
city: Sumida-Ku
country: Japan
facility: Tokyo Teishin Hospital
state: Tokyo
city: Kumamoto
country: Japan
facility: Ohyama Dermatology Clinic
city: Tokyo
country: Japan
facility: Tokyo Medical University Hospital
city: Sakai-Shi
country: Japan
facility: Dermatology and Ophthalmology Kume Clinic
state: Ôsaka
city: Wonju-si
country: Korea, Republic of
facility: Yonsei University Wonju Severance Christian Hospital
state: Gangwon-do
city: Gwangju
country: Korea, Republic of
facility: Chosun University Hospital
state: Gwangju Gwang'yeogsi
city: Beon-gil Bundang-gu
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
city: Bucheon-si
country: Korea, Republic of
facility: The Catholic University of Korea, Bucheon St. Mary's Hospital
state: Gyeonggido
city: Gwangjin-Gu
country: Korea, Republic of
facility: Konkuk University Medical Center
state: Seoul Teugbyeolsi
city: Seocho-Gu
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Mary's Hospital
state: Seoul Teugbyeolsi
city: Seoul
country: Korea, Republic of
facility: Soon Chun Hyang University Hospital Seoul
state: Seoul Teugbyeolsi
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Chung-Ang University Hospital
city: Talsi
country: Latvia
facility: Smite Aija medical practice in dermatology, venerology
state: Talsu Aprinkis
city: Kuldīga
country: Latvia
facility: Semigallia
city: Riga
country: Latvia
facility: Riga 1st Hospital
city: Riga
country: Latvia
facility: Aesthetic dermatology clinic of prof. J. Kisis
city: Riga
country: Latvia
facility: Health Center 4-1 Grebenscikova Str
city: Riga
country: Latvia
facility: Veseliba un estetika Ltd.
city: Riga
country: Latvia
facility: Outpatient Clinic Adoria
city: Riga
country: Latvia
facility: Health Center 4-Skanstes iela 50
city: Katowice
country: Poland
facility: Centrum Medyczne Katowice - PRATIA
state: Dolnoslaskie
city: Klodzko
country: Poland
facility: Globe Badania Kliniczne Spolka z o.o. - Klodzko
state: Dolnoslaskie
city: Wroclaw
country: Poland
facility: Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p
state: Dolnoslaskie
city: Skierniewice
country: Poland
facility: Velocity Skierniewice Sp. z o.o.
state: Lodzkie
city: Łódź
country: Poland
facility: Dermoklinika-Centrum Medyczne s.c
state: Lodzkie
city: Lublin
country: Poland
facility: Clinical Best Solutions Sp. z o.o. S.K.
state: Lubelskie
city: Lublin
country: Poland
facility: Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska
state: Lubelskie
city: Lódz
country: Poland
facility: Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A.
state: Lódzkie
city: Krakow
country: Poland
facility: Centrum Medyczne ALL-MED
state: Malopolskie
city: Krakow
country: Poland
facility: Pratia MCM Krakow
state: Malopolskie
city: Kraków
country: Poland
facility: Krakowskie Centrum Medyczne Sp. z o.o.
state: Malopolskie
city: Nadarzyn
country: Poland
facility: Rheumatology Clinic NZOZ Lecznica MAK-MED
state: Mazowieckie
city: Siedlce
country: Poland
facility: ETG Siedlce - PPDS
state: Mazowieckie
city: Sochaczew
country: Poland
facility: RCMed Oddzial Sochaczew
state: Mazowieckie
city: Warsaw
country: Poland
facility: Klinika Reuma Park sp . zoo Sp.k.
state: Mazowieckie
city: Warszawa
country: Poland
facility: Clinical Best Solutions Sp. z o.o. S.K.
state: Mazowieckie
city: Warszawa
country: Poland
facility: MICS Centrum Medyczne Warszawa
state: Mazowieckie
city: Warszawa
country: Poland
facility: Clinical Research Group Sp. z o.o
state: Mazowieckie
city: Warszawa
country: Poland
facility: High-Med Przychodnia Specjalistyczna
state: Mazowieckie
city: Warszawa
country: Poland
facility: AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie
state: Mazowieckie
city: Warszawa
country: Poland
facility: ETG Warszawa - PPDS
state: Mazowieckie
city: Warszawa
country: Poland
facility: Klinika Ambroziak Dermatologia
state: Mazowieckie
city: Warszawa
country: Poland
facility: FutureMeds - Targowek - PPDS
state: Mazowieckie
city: Bialystok
country: Poland
facility: NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik
state: Podlaskie
city: Bialystok
country: Poland
facility: ClinicMed Daniluk, Nowak Spolka Komandytowa
state: Podlaskie
city: Gdansk
country: Poland
facility: AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku
state: Pomorskie
city: Gdansk
country: Poland
facility: Copernicus Podmiot Leczniczy Sp. z o.o, Szpital Sw. Wojciecha, Oddzial Dermatologii
state: Pomorskie
city: Gdansk
country: Poland
facility: Centrum Badan Klinicznych Pi-house Sp. Z O. O.
state: Pomorskie
city: Gdynia
country: Poland
facility: Derm-art
state: Pomorskie
city: Katowice
country: Poland
facility: AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Katowicach
state: Slaskie
city: Katowice
country: Poland
facility: Centrum Medyczne Angelius Provita
state: Slaskie
city: Katowice
country: Poland
facility: Pro Familia Altera Sp. z o.o.
state: Slaskie
city: Ostrowiec Swietokrzyski
country: Poland
facility: Dermedic Jacek Zdybski
state: Swietokrzyskie
city: Ostrowiec Swietokrzyski
country: Poland
facility: Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.
state: Swietokrzyskie
city: Poznan
country: Poland
facility: AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu
state: Wielkopolskie
city: Poznań
country: Poland
facility: Twoja Przychodnia PCM
state: Wielkopolskie
city: Szczecin
country: Poland
facility: Twoja Przychodnia Szczecińskie Centrum Medyczne Sp. z o.o.
state: Zachodniopomorskie
city: Bochnia
country: Poland
facility: Centrum Uslug Medycznych MaxMed
city: Bydgoszcz
country: Poland
facility: Centrum Medyczne Bydgoszcz- PRATIA
city: Elblag
country: Poland
facility: Ambulatorium Sp. z o.o.
city: Krakow
country: Poland
facility: Promed P. Lach R. Głowacki Sp. j., Centrum Medyczne Promed
city: Krakow
country: Poland
facility: Diamond Clinic Sp. z o.o., Diamond Medical Center
city: Lodz
country: Poland
facility: Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Lodzi, Klinika Dermatologii i Wenerologii
city: Lublin
country: Poland
facility: Pro Life Medica Sp. z o.o. ETG Lublin
city: Nowa Sól
country: Poland
facility: Twoja Przychodnia - Nowosolskie Centrum Medyczne sp. z o.o
city: Olsztyn
country: Poland
facility: ETYKA Osrodek Badan Klinicznych
city: Torun
country: Poland
facility: MICS Centrum Medyczne Torun
city: Warszawa
country: Poland
facility: Royalderm Agnieszka Nawrocka
city: Wrocław
country: Poland
facility: dermMEDICA Sp. z o.o. | Krzysztofa Kolumba 6
city: San Juan
country: Puerto Rico
facility: GCM Medical Group
city: San Sebastian
country: Spain
facility: Hospital Clinico San Carlos
state: Guipúzcoa
city: Las Palmas de Gran Canaria
country: Spain
facility: Hospital Universitario de Gran Canaria Doctor Negrin
state: LAS Palmas
city: Manises
country: Spain
facility: Hospital de Manises
state: Valencia
city: Barcelona
country: Spain
facility: Hospital de La Santa Creu i Sant Pau - Dermatologia
city: Tainan
country: Taiwan
facility: National Cheng Kung University
state: Tainan City
city: Hsinchu City
country: Taiwan
facility: National Taiwan University Hospital, Hsin-Chu Branch
city: Kaohsiung City
country: Taiwan
facility: Kaohsiung Veterans General Hospital
city: Taipei City
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taipei
country: Taiwan
facility: Mackay Memorial Hospital-Taipei branch
city: Zhong Zheng Qu
country: Taiwan
facility: National Taiwan University Hospital
city: High Wycombe
country: United Kingdom
facility: Velocity Clinical Research - High Wycombe - PPDS
state: Buckinghamshire
city: Ilford
country: United Kingdom
facility: 4 Medical Clinical Solutions - Swinton - PPDS
state: Essex
city: Chorley
country: United Kingdom
facility: Accellacare of Yorkshire
state: Lancashire
city: Salford
country: United Kingdom
facility: Salford Royal Hospital - PPDS
state: Lancashire
city: London
country: United Kingdom
facility: Whipps Cross University Hospital
state: London, City Of
city: Harrow
country: United Kingdom
facility: Accellacare of Northamptonshire
state: Middlesex
city: London
country: United Kingdom
facility: Velocity Clinical Research North London - Percy Road - PPDS
state: Middlesex
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: